The epidemiology of lymphangioleiomyomatosis in Japan: A nationwide cross-sectional study of presenting features and prognostic factors

Respirology

Volumn 12, Issue 4, 2007, Pages 523-530

  Hayashida, Mie ^a   Seyama, Kuniaki ^b   Inoue, Yoshikazu ^c   Fujimoto, Keisaku ^a   Kubo, Keishi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

Author keywords

Lung function; Lymphangioleiomyomatosis; Phenotype; Presenting features; Prognosis

Indexed keywords

ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DETERIORATION; DIFFERENTIAL DIAGNOSIS; DYSPNEA; HEALTH SURVEY; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPAN; KAPLAN MEIER METHOD; LYMPHANGIOLEIOMYOMATOSIS; MAJOR CLINICAL STUDY; PNEUMOTHORAX; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; QUESTIONNAIRE;

ADULT; CROSS-SECTIONAL STUDIES; HUMANS; JAPAN; LYMPHANGIOLEIOMYOMATOSIS; PROGNOSIS; RESPIRATORY FUNCTION TESTS; SURVIVAL ANALYSIS;

EID: 34250756514     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2007.01101.x     Document Type: Article

References (26)

1. Kelly J, Moss J. Lymphangioleiomyomatosis. Am. J. Med. Sci. 2001 321 : 17 25.
2. Strizheva GD, Carsillo T, Kruger WD, Sullivan EJ, Ryu JH et al. The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis. Am. J. Respir. Crit. Care Med. 2001 163 : 253 8.
3. Sato T, Seyama K, Fujii H, Maruyama H, Setoguchi Y et al. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J. Hum. Genet 2002 47 : 20 8.
4. Pacheco-Rodriguez G, Kristof AS, Stevens LA, Zhang Y, Crooks D et al. Filley Lecture. Genetics and gene expression in lymphangioleiomyomatosis. Chest 2002 121 : 56S 60S.
5. Zhe X, Yang Y, Schuger L. Imbalanced plasminogen system in lymphangioleiomyomatosis: potential role of serum response factor. Am. J. Respir. Cell Mol. Biol. 2005 32 : 28 34.
6. Inoue Y, King TE Barker E, Daniloff E, Newman LS. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am. J. Respir. Crit. Care Med. 2002 166 : 765 73.
7. Ryu JH, Moss J, Beck GJ, Lee JC, Brown KK et al. The NHLBI lymphangioleiomyomatosis registry. Characteristics of 230 patients at enrollment. Am. J. Respir. Crit. Care Med. 2006 173 : 105 11.
8. Cohen MM, Pollock-BarZiv S, Johnson SR. Emerging clinical picture of lymphangioleiomyomatosis. Thorax 2005 60 : 875 9.
9. Johnson SR, Tattersfield AE. Clinical experience of lymphangioleiomyomatosis in the UK. Thorax 2000 55 : 1052 7.
10. Urban T, Lazor R, Lacronique J, Murris M, Labrune S et al. Pulmonary lymphangioleiomyomatosis: a study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies 'Orphelines' Pulmonaires (GERM'O'P). Medicine 1999 78 : 321 37.
11. Kitaichi M, Nishimura K, Itoh H, Izumi T. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am. J. Respir. Crit. Care Med. 1995 151 : 527 33.
12. Avila NA, Kelly JA, Chu SC, Dwyer AJ, Moss J. Lymphangioleiomyomatosis: abdominopelvic CT and US findings. Radiology 2000 216 : 147 53.
13. Taylor JR, Ryu J, Colby TV, Raffin TA. Lymphangioleiomyomatosis: clinical course in 32 patients. N. Engl. J. Med. 1990 323 : 1254 60.
14. Seyama K, Kira S, Takahashi H, Ohnishi M, Kodama Y et al. Longitudinal follow-up study of 11 patients with pulmonary lymphangioleiomyomatosis: diverse clinical courses of LAM allow some patients to be treated without anti-hormone therapy. Respirology 2001 6 : 331 40.
15. Lazor R, Valeyre D, Lacronique J, Wallaert B, Urbane T et al. The Groupe d'Etudes et de Recherche sur les Maladies 'Orphelines' Pulmonaires (GERM'O'P). Low initial KCO predicts rapid FEV1 decline in pulmonary lymphangioleiomyomatosis. Respir. Med. 2004 98 : 536 41.
16. Silverstein EF, Ellis K, Wolff M, Jaretzki A 3rd. Pulmonary lymphangiomyomatosis. Am. J. Roentgenol. Radium. Ther. Nucleic Med. 1974 120 : 832 50.
17. Corrin B, Liebow AA, Friedman PJ. Pulmonary lymphangiomyomatosis: a review. Am. J. Pathol. 1975 79 : 348 82.
18. Johnson SR, Whale CI, Hubbard RB, Lewis SA, Tattersfield AE. Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax 2004 59 : 800 3.
19. Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am. J. Respir. Crit. Care Med. 1999 160 : 628 33.
20. Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Kristof AS, Avila NA et al. Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis. Am. J. Respir. Crit. Care Med. 2003 168 : 1427 31.
21. Sietsema KE, McCormack FX. Lymphangioleiomyomatosis: insights about, and from, a rare disease. Am. J. Respir. Crit. Care Med. 2003 168 : 1405 6.
22. Matsui K, Beasley MB, Nelson WK, Barnes PM, Bechtle J et al. Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am. J. Surg. Pathol. 2001 25 : 479 84.
23. Burger CD, Hyatt RE, Staats BA. Pulmonary mechanics in lymphangio- leiomyomatosis. Am. Rev. Respir. Dis. 1991 143 : 1030 3.
24. Paciocco G, Uslenghi E, Bianchi A, Mazzarella G, Roviaro GC et al. Diffuse cystic lung diseases: correlation between radiologic and functional status. Chest 2004 125 : 135 42.
25. Avila NA, Kelly JA, Dwyer AJ, Johnson DL, Jones EC et al. Lymphangioleiomyomatosis: correlation of qualitative and quantitative thin-section CT with pulmonary function tests and assessment of dependence on pleurodesis. Radiology 2002 223 : 189 97.
26. Crausman RS, Lynch DA, Mortenson RL, King TE Jr, Irvin CG et al. Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangioleiomyomatosis. Chest 1996 109 : 131 7.